BPC-157: complete research guide

If you've been researching recovery peptides, you've probably come across BPC-157. It's frequently mentioned in discussions about tendon healing, injury recovery, gut repair, and even nerve regeneration. Some people describe it as one of the most promising experimental peptides available.

But what does the research actually say? And what should you understand before considering it?

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It's derived from a protein found naturally in human gastric juice. The "body protection compound" name comes from its observed protective effects on various tissues in animal studies.

The peptide was first identified and characterized by researchers at the University of Zagreb in Croatia, who have produced the majority of published research on it.

Mechanism of action

BPC-157 appears to work through several pathways, though the complete picture is still being studied:

• Angiogenesis: BPC-157 promotes the formation of new blood vessels, which is critical for tissue repair. It upregulates VEGF (vascular endothelial growth factor) expression.
• Nitric oxide system: The peptide interacts with the nitric oxide (NO) system, which plays a role in blood flow regulation and inflammation modulation.
• Growth factor modulation: Studies show BPC-157 influences the expression of several growth factors involved in tissue repair and regeneration.
• FAK-paxillin pathway: This signaling pathway is involved in cell migration and adhesion, both essential for wound healing.

What the animal research shows

The animal data on BPC-157 is genuinely impressive in scope. Studies have demonstrated effects including accelerated healing of tendons, ligaments, and muscles, protection against NSAID-induced gut damage, improved healing of skin wounds and burns, neuroprotective effects in brain injury models, and positive effects on bone healing.

However, there's a critical caveat that most peptide websites gloss over.

The human evidence gap

This doesn't mean BPC-157 doesn't work in humans. It means we don't know with scientific certainty that it does, what the optimal human dosing is, what the long-term safety profile looks like, or what drug interactions may exist.

The University of Zagreb group has referenced human studies in various contexts, but complete published data from controlled human trials has not appeared in the peer-reviewed literature.

Commonly discussed protocols

The following dosing information comes from community reports and should not be taken as medical advice. There is no established human dosing for BPC-157.

Community-reported approaches typically involve subcutaneous injection near the injury site at doses ranging from 200–500mcg once or twice daily, with cycles lasting 4–8 weeks. Oral administration is also discussed, particularly for gut-related applications, typically at higher doses — for gut-specific inflammation, some users also explore KPV, a targeted anti-inflammatory peptide with its own gut health research. If you're new to injectable peptides, see our step-by-step reconstitution guide before getting started, use our reconstitution calculator to determine the exact number of units to draw for your dose, and review our peptide storage and handling guide to maintain potency once reconstituted.

Safety considerations

Based on the available animal data, BPC-157 appears to have a favorable safety profile with no reported LD50 (lethal dose) established because researchers couldn't reach a lethal dose in animal studies. However, the absence of human trial data means we cannot make definitive safety claims.

Potential concerns that warrant caution include its effects on angiogenesis (new blood vessel formation), which could theoretically be problematic for individuals with certain cancers. Interactions with other medications have not been formally studied. Long-term effects beyond the duration of animal studies are unknown. For a broader look at what to watch for across peptide categories, see our peptide side effects and safety guide.

The bottom line

BPC-157 has a compelling animal research profile that suggests significant therapeutic potential for tissue repair and healing. See our BPC-157 vs TB-500 comparison for a detailed head-to-head, or our broader guide to the best peptides for injury recovery for how it stacks up against other options. Some users also combine BPC-157 with growth hormone peptides like CJC-1295 and ipamorelin for recovery support, though this combination has not been formally studied — our peptide stacking guide covers the principles behind combining peptides safely. The KLOW peptide blend, which pairs BPC-157 with TB-500, GHK-Cu, and KPV in a single formulation, reflects growing interest in multi-pathway recovery stacks. If you're weighing different combinations, our peptide stack builder can help you match peptides to your specific recovery goals. The breadth of the animal data is unusual and noteworthy. However, the complete absence of published human clinical trials represents a significant gap that honest reporting requires acknowledging.

If you're interested in BPC-157, discuss it with a qualified healthcare professional who can evaluate your specific situation, potential drug interactions, and help you weigh the risk-benefit ratio based on the available evidence.